Close Menu

NEW YORK (GenomeWeb) – Twist Bioscience has filed with the US Securities and Exchange Commission for a proposed public offering of 3 million shares of its common stock, the firm said after the close of the market on Monday.

In addition, it will grant the underwriters a 30-day option to purchase an additional 450,000 shares of common stock at the public offering price. Twist has not yet priced the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.